The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
The Potential for microRNA Therapeutics and Clinical Research
Open accessAbstract
As FDA-approved small RNA drugs start to enter clinical medicine, ongoing studies for the microRNA (miRNA) class of small RNAs expand its preclinical and clinical research applications. A growing number of reports suggest a significant utility of miRNAs as biomarkers for pathogenic conditions, modulators of drug resistance, and/or as drugs for medical intervention in almost all human health conditions. The pleiotropic nature of this class of nonprotein-coding RNAs makes them particularly attractive drug targets for diseases with a multifactorial origin and no current effective treatments. As candidate miRNAs begin to proceed toward initiation and completion of potential phase 3 and 4 trials in the future, the landscape of both diagnostic and interventional medicine will arguably continue to evolve. In this mini-review, we discuss miRNA drug discovery development and their current status in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Guo, J., Jin, D., Wu, Y., Yang, L., Du, J., Gong, K., Chen, W., Dai, J., Miao, S., & Xi, S. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.001 · Cited by 64
RetractedInitial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Finishing the euchromatic sequence of the human genome
International Human Genome Sequencing Consortium (2004) · Nature · doi:10.1038/nature03001 · Cited by 4,971
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
The MicroRNA Spectrum in 12 Body Fluids
Weber, J. A., Baxter, D. H., Zhang, S., Huang, D. Y., How Huang, K., Jen Lee, M., Galas, D. J., & Wang, K. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.147405 · Cited by 2,477
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Cited by
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Goodall, G. J., & Wickramasinghe, V. O. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00306-0 · Cited by 1,066
Ratti, M., Lampis, A., Ghidini, M., Salati, M., Mirchev, M. B., Valeri, N., & Hahne, J. C. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00717-x · Cited by 606
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 544
Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
Lu, Y., Chan, Y.-T., Tan, H.-Y., Li, S., Wang, N., & Feng, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01197-3 · Cited by 499
Yamaguchi, H., Hsu, J.-M., Yang, W.-H., & Hung, M.-C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 493
RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies
Kim, T., & Croce, C. M. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01050-9 · Cited by 407
Trials and Tribulations of MicroRNA Therapeutics
Seyhan, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031469 · Cited by 381
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Traber, G. M., & Yu, A.-M. (2023) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001234 · Cited by 291
Six Shades of Vascular Smooth Muscle Cells Illuminated by KLF4 (Krüppel-Like Factor 4)
Yap, C., Mieremet, A., de Vries, C. J. M., Micha, D., & de Waard, V. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.121.316600 · Cited by 278
Targeting Notch in oncology: the path forward
Majumder, S., Crabtree, J. S., Golde, T. E., Minter, L. M., Osborne, B. A., & Miele, L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00091-3 · Cited by 270
Azwar, S., Seow, H. F., Abdullah, M., Faisal Jabar, M., & Mohtarrudin, N. (2021) · Biology · doi:10.3390/biology10090854 · Cited by 173
A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis
Chioccioli, M., Roy, S., Newell, R., Pestano, L., Dickinson, B., Rigby, K., Herazo-Maya, J., Jenkins, G., Ian, S., Saini, G., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104304 · Cited by 129
Oh, Y. M., Lee, S. W., Kim, W. K., Chen, S., Church, V. A., Cates, K., Li, T., Zhang, B., Dolle, R. E., Dahiya, S., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01185-4 · Cited by 100
Role of microRNAs in glioblastoma
Chen, M., Medarova, Z., & Moore, A. (2021) · Oncotarget · doi:10.18632/oncotarget.28039 · Cited by 84
Current advances in non‐viral gene delivery systems: Liposomes versus extracellular vesicles
Belhadj, Z., Qie, Y., Carney, R. P., Li, Y., & Nie, G. (2023) · BMEMat · doi:10.1002/bmm2.12018 · Cited by 79
A microRNA signature that correlates with cognition and is a target against cognitive decline
Islam, M. R., Kaurani, L., Berulava, T., Heilbronner, U., Budde, M., Centeno, T. P., Elerdashvili, V., Zafieriou, M., Benito, E., Sertel, S. M., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013659 · Cited by 74
BAP31: Physiological functions and roles in disease
Quistgaard, E. M. (2021) · Biochimie · doi:10.1016/j.biochi.2021.04.008 · Cited by 70
The role of MiRNA-21 in gliomas: Hope for a novel therapeutic intervention?
Aloizou, A.-M., Pateraki, G., Siokas, V., Mentis, A.-F. A., Liampas, I., Lazopoulos, G., Kovatsi, L., Mitsias, P. D., Bogdanos, D. P., Paterakis, K., et al. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.11.001 · Cited by 69
El-Derany, M. O., & AbdelHamid, S. G. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114624 · Cited by 64
snoRNAs offer novel insight and promising perspectives for lung Cancer understanding and management
Mourksi, N.-E.-H., Morin, C., Fenouil, T., Diaz, J.-J., & Marcel, V. (2020) · Cells · doi:10.3390/cells9030541 · Cited by 62
Cell type–specific microRNA therapies for myocardial infarction
Liu, B., Wang, B., Zhang, X., Lock, R., Nash, T., & Vunjak-Novakovic, G. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd0914 · Cited by 53
“12 of 21 is thus not surprising that of the current miRNA therapeutics in either phase 1 or 2 clinical trials, the majority are ASOs targeting a specific miRNA (180), although mimics are also being tested.”
BackgroundLDL Receptor Pathway Regulation by miR-224 and miR-520d
Salerno, A. G., van Solingen, C., Scotti, E., Wanschel, A. C. B. A., Afonso, M. S., Oldebeken, S. R., Spiro, W., Tontonoz, P., Rayner, K. J., & Moore, K. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00081 · Cited by 33
Herman, A. B., Anerillas, C., Harris, S. C., Munk, R., Martindale, J. L., Yang, X., Mazan-Mamczarz, K., Zhang, Y., Heckenbach, I. J., Scheibye-Knudsen, M., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab538 · Cited by 31
Roles of microRNAs in Gastrointestinal Cancer Stem Cell Resistance and Therapeutic Development
Hwang, G.-R., Yuen, J. G., & Ju, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041624 · Cited by 15
Metadata
- Authors
- Hanna, J., Hossain, G. S., & Kocerha, J.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2019-05-16
- Volume
- 10
- Pages
- 478-478
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W2946714259
- Cited by
- 726
- References
- 56
- FWCI
- 31.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.